REGULATION OF MUSCLE GLYCOGEN-METABOLISM BY CGRP AND AMYLIN - CGRP RECEPTORS NOT INVOLVED

被引:37
|
作者
BEAUMONT, K
PITTNER, RA
MOORE, CX
WOLFELOPEZ, D
PRICKETT, KS
YOUNG, AA
RINK, TJ
机构
[1] Amylin Pharmaceuticals, Inc, San Diego, California, 92121
关键词
AMYLIN; CGRP; DIABETES; INSULIN RESISTANCE; GLYCOGEN; GLUCOSE METABOLISM; PEPTIDE RECEPTORS; CALCITONIN;
D O I
10.1111/j.1476-5381.1995.tb14991.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the present study was to determine whether amylin and calcitonin gene-related peptide (CGRP) act through shared or distinct receptors to inhibit insulin-stimulated incorporation of [C-14]-glucose into glycogen. Rat amylin was 3 fold more potent than either rat alpha CGRP or rat beta CGRP at reducing glycogen synthesis from [C-14]-glucose in insulin-treated rat soleus muscle. This action was blocked by peptide antagonists, with the rank order of potency being AC187>salmon calcitonin(8-32) (sCT(8-32)) > h-alpha CGRP(8-37) for antagonism of either amylin or CGRP. The antagonist potency order correlated with affinity for amylin receptors measured in rat nucleus accumbens but not CGRP receptors measured in rat L6 muscle cells. Inhibition of glucose incorporation into glycogen by amylin and CGRP appears to be mediated by shared receptors that have the pharmacological characteristics of amylin receptors, and are distinct from previously described CGRP receptors.
引用
收藏
页码:713 / 715
页数:3
相关论文
共 24 条
  • [1] CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?
    Walker, C. S.
    Hay, D. L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (07) : 1293 - 1307
  • [2] Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
    Sonne, Nina
    Karsdal, Morten A.
    Henriksen, Kim
    MOLECULAR METABOLISM, 2020, 46
  • [3] Amylin-induced suppression of ANP secretion through receptors for CGRP1 and salmon calcitonin
    Piao, FL
    Cao, CH
    Han, JH
    Kim, SZ
    Cho, KW
    Kim, SH
    REGULATORY PEPTIDES, 2004, 117 (03) : 159 - 166
  • [4] REGULATION OF GLYCOGEN-METABOLISM IN THE LIVER
    MORAND, C
    REMESY, C
    DEMIGNE, C
    DIABETES & METABOLISM, 1992, 18 (1BIS): : 87 - 95
  • [5] Different pharmacological characteristics in L(6) and C2C12 muscle cells and intact rat skeletal muscle for amylin, CGRP and calcitonin
    Pittner, RA
    WolfeLopez, D
    Young, AA
    Beaumont, K
    BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (05) : 847 - 852
  • [6] EFFECTS OF ISLET AMYLOID POLYPEPTIDE (AMYLIN) AND CALCITONIN GENE-RELATED PEPTIDE (CGRP) ON GLUCOSE-METABOLISM IN THE RAT
    MORISHITA, T
    YAMAGUCHI, A
    YAMATANI, T
    NAKAMURA, A
    ARIMA, N
    YAMASHITA, Y
    NAKATA, H
    FUJITA, T
    CHIBA, T
    DIABETES RESEARCH AND CLINICAL PRACTICE, 1992, 15 (01) : 63 - 70
  • [7] Non-competitive antagonism of amylin on CGRP1-receptors in rat coronary small arteries
    Sheykhzade, M
    Nyborg, NCB
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (02) : 386 - 390
  • [8] 8-37H-CGRP ANTAGONIZES ACTIONS OF AMYLIN ON CARBOHYDRATE-METABOLISM INVITRO AND INVIVO
    WANG, MW
    YOUNG, AA
    RINK, TJ
    COOPER, GJS
    FEBS LETTERS, 1991, 291 (02) : 195 - 198
  • [9] CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (W098/11128), a non-peptide antagonist
    Hasbak, P
    Sams, A
    Schifter, S
    Longmore, J
    Edvinsson, L
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (08) : 1405 - 1413
  • [10] PATIENTS WITH CHRONIC GLUCOCORTICOID TREATMENT DEVELOP CHANGES IN MUSCLE GLYCOGEN-METABOLISM
    FERNANDEZSOLA, J
    CUSSO, R
    PICADO, C
    VERNET, M
    GRAU, JM
    URBANOMARQUEZ, A
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1993, 117 (1-2) : 103 - 106